On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.

The rally was driven by a confluence of recent catalysts. The company's xT CDx next-generation sequencing platform recently received FDA approval for tumor-only comprehensive genomic profiling of solid tumors, making Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The approval is expected to deliver an estimated $200 increase in average selling price starting next year. Additionally, the company launched Lens, a next-generation agentic AI platform for oncology drug development designed to help teams optimize clinical trial designs and accelerate evidence generation.

The broader Life Sciences Tools and Services sector rallied in tandem, with Bio-Techne up 19.33%, Repligen up 5.76%, Thermo Fisher Scientific up 4.13%, Danaher up 4.09%, and West Pharmaceutical up 2.67%, providing further sector-wide tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)